Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic

Sunyu Kang, Kevin Gergich, Gregory M. Lubiniecki et al. · Annals of Oncology · 2017

The landscape of cancer treatment has undergone a vast change over the past four decades [1,2]. Discovery of the heterogeneous molecular features of tumors and the associated microenvironment has led to the development of novel classes of targeted therapeutics [3–5], the two main types of which are small-molecule inhibitors and monoclonal antibodies (mAbs) [1–3]. These targeted drugs have furthered the development of personalized therapeutic regimens in oncology.

Cited by 110 works. doi:10.1093/annonc/mdx076 Open-access PDF

Authors

References